SLC1A5 and serous adenocarcinoma: As there was no differences in this study for SLC1A5 positivity between serous and non-serous tumors or the type of given post-surgical chemotherapy between those two main histological subgroups, it could be concluded, that the protective effect of SLC1A5 in non-serous carcinoma was not associated with drug resistance, but by some other biological property.